Originally published byEU-Startups
BioLamina, a Stockholm-based BioTech scale-up specialising in matrix biology and cell culture, has secured a €20 million financing commitment from the European Investment Bank (EIB) to enable cell therapies for serious chronic diseases. The EIB loan is structured as venture debt, a form of long-term financing aimed at innovative, rapidly expanding companies. It complements venture […]
The post Stockholm’s BioLamina secures €20 million EIB loan to scale cell therapies for chronic diseases appeared first on EU-Startups.
🌐
More news from European UnionEuropean Union
EUROPE
Related News
Securing the Untrusted Agentic Development Layer
1d ago
Inside Legora’s hunt for legal tech acquisitions
14h ago
The talent profile Europe's top AI scaleups are chasing
14h ago
A PhD pivot, a stint in VC and a rumoured Anthropic deal: why Europe is watching Walter Goodwin
1d ago
Linux kernel maintainers pitch emergency killswitch after CopyFail and Dirty Frag chaos
2d ago